Tovetumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTovetumab
Drug Alias Name托维妥单抗tovetumabum托维妥人单抗MEDI-575
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionPlatelet-derived growth factor receptor alpha modulators
TargetsPlatelet-derived growth factor receptor alpha
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungGlioblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCambridge Antibody Technology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcMedimmune Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungGlioblastoma +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG